Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

257 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial.
Dieci MV, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Giotta F, Aieta M, Gebbia V, Musolino A, Garrone O, Donadio M, Rimanti A, Beano A, Zamagni C, Soto Parra H, Piacentini F, Danese S, Ferro A, Cagossi K, Sarti S, Gambaro AR, Romito S, Bazan V, Amaducci L, Moretti G, Foschini MP, Balduzzi S, Vicini R, D'Amico R, Griguolo G, Guarneri V, Conte PF. Dieci MV, et al. Among authors: bazan v. BMC Med. 2019 Nov 21;17(1):207. doi: 10.1186/s12916-019-1445-z. BMC Med. 2019. PMID: 31747948 Free PMC article. Clinical Trial.
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients.
Passiglia F, Galvano A, Castiglia M, Incorvaia L, Calò V, Listì A, Mazzarisi S, Perez A, Gallina G, Rizzo S, Soto Parra H, Bazan V, Russo A. Passiglia F, et al. Among authors: bazan v. Ther Adv Med Oncol. 2019 Apr 16;11:1758835919839928. doi: 10.1177/1758835919839928. eCollection 2019. Ther Adv Med Oncol. 2019. PMID: 31019571 Free PMC article.
The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.
Russo A, Bazan V, Iacopetta B, Kerr D, Soussi T, Gebbia N; TP53-CRC Collaborative Study Group. Russo A, et al. Among authors: bazan v. J Clin Oncol. 2005 Oct 20;23(30):7518-28. doi: 10.1200/JCO.2005.00.471. Epub 2005 Sep 19. J Clin Oncol. 2005. PMID: 16172461 Review.
Male breast cancer.
Ottini L, Palli D, Rizzo S, Federico M, Bazan V, Russo A. Ottini L, et al. Among authors: bazan v. Crit Rev Oncol Hematol. 2010 Feb;73(2):141-55. doi: 10.1016/j.critrevonc.2009.04.003. Epub 2009 May 7. Crit Rev Oncol Hematol. 2010. PMID: 19427229 Review.
Stabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?
Fanale D, Bronte G, Passiglia F, Calò V, Castiglia M, Di Piazza F, Barraco N, Cangemi A, Catarella MT, Insalaco L, Listì A, Maragliano R, Massihnia D, Perez A, Toia F, Cicero G, Bazan V. Fanale D, et al. Among authors: bazan v. Anal Cell Pathol (Amst). 2015;2015:690916. doi: 10.1155/2015/690916. Epub 2015 Sep 21. Anal Cell Pathol (Amst). 2015. PMID: 26484003 Free PMC article. Review.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Incorvaia L, et al. Among authors: bazan v. Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20. Adv Ther. 2019. PMID: 31432460 Free PMC article. Review.
257 results